-
1 Comment
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Vincerx Pharma, Inc gets an overall score of 1/5.
| ISIN | None |
|---|---|
| Exchange | NASDAQ |
| CurrencyCode | USD |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | None |
|---|---|
| PE Ratio | None |
| Target Price | None |
| Beta | nan |
| Dividend Yield | None |
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops new therapies to address unmet medical needs for the treatment of cancer. The company's lead product candidate is VIP152 that is in clinical trials. Its drug candidates are in development for the treatment of solid tumors, leukemia, B-cell malignancies, lymphomas, and myelodysplastic syndrome. Vincerx Pharma, Inc. is based in Palo Alto, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for VINCU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
